Stock Analiz

Integra Lifesciences Holdings Corp. (IART) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Integra Lifesciences Holdings’s revenue went from $992M in fiscal 2016 to $1.6B in fiscal 2025, growth of about 5.7% a year.

Net income in fiscal 2025 was -$516M, a net margin of -31.6%; the best year in this period was 2022 with $181M.

Over the twelve months to September 30, 2026, revenue was $1.7B and net income $13M.

Free cash flow was -$31M in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count fell 3% over the period (buybacks).

Revenue, profit and cash flow by year

Revenue
2016: $992M162017: $1.2B172018: $1.5B182019: $1.5B192020: $1.4B202021: $1.5B212022: $1.6B222023: $1.5B232024: $1.6B242025: $1.6B25$1.6B
Net income
2016: $75M162017: $65M172018: $61M182019: $50M192020: $134M202021: $169M212022: $181M222023: $68M232024: -$7M242025: -$516M25-$516M
Free cash flow
2016: $69M162017: $71M172018: $122M182019: $162M192020: $165M202021: $264M212022: $222M222023: $73M232024: $25M242025: -$31M25-$31M
EPS (diluted)
2016: $0.94162017: $0.82172018: $0.72182019: $0.58192020: $1.57202021: $1.98212022: $2.16222023: $0.84232024: $-0.09242025: $-6.7425$-6.74

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.7B$1.6B$1.6B$1.5B$1.6B$1.5B$1.4B$1.5B$1.5B$1.2B$992M
Gross profit$867M$832M$882M$885M$970M$945M$851M$953M$901M$753M$643M
Operating income$73M-$493M$28M$112M$239M$197M$151M$94M$111M$45M$115M
Net income$13M-$516M-$7M$68M$181M$169M$134M$50M$61M$65M$75M
EPS (diluted)$0.17$-6.74$-0.09$0.84$2.16$1.98$1.57$0.58$0.72$0.82$0.94
R&D$94M$99M$115M$104M$101M$93M$77M$80M$78M$63M$58M
Revenue growth—+1.5%+4.5%−1.0%+1.0%+12.4%−9.6%+3.1%+23.9%+19.8%+12.4%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$140M$50M$129M$140M$264M$312M$204M$231M$200M$115M$116M
Capital spending-$55M-$81M-$104M-$67M-$42M-$48M-$39M-$70M-$78M-$44M-$47M
Free cash flow$86M-$31M$25M$73M$222M$264M$165M$162M$122M$71M$69M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$0$221000$52M$275M$125M$0$100M$0$0——
Stock-based pay$20M$19M$24M$20M$28M$36M$20M$21M$21M$22M$17M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$264M$274M$309M$457M$513M$470M$199M$139M$175M$102M
Debt—$1.9B$942M$957M$947M$949M$978M$987M$1.2B$1.8B$0
Equity—$1.0B$1.5B$1.6B$1.8B$1.7B$1.5B$1.4B$1.4B$962M$840M
Total assets—$3.6B$4.0B$3.8B$3.9B$3.8B$3.6B$3.3B$3.1B$3.2B$1.8B
Shares (diluted)79M77M77M80M84M85M85M86M84M79M79M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin52.4%50.9%54.8%57.4%62.3%61.2%62.0%62.8%61.2%63.3%64.8%
Operating margin4.4%-30.2%1.8%7.2%15.3%12.8%11.0%6.2%7.5%3.8%11.6%
Net margin0.8%-31.6%-0.4%4.4%11.6%11.0%9.8%3.3%4.1%5.5%7.5%
FCF margin5.2%-1.9%1.6%4.7%14.3%17.1%12.0%10.7%8.3%6.0%7.0%
ROIC—-15.3%0.9%3.7%7.3%5.9%4.8%3.3%3.4%1.3%11.3%
ROE—-49.5%-0.4%4.3%10.0%10.0%8.8%3.5%4.4%6.7%8.9%

Frequently asked questions

What is Integra Lifesciences Holdings’s annual revenue?

$1.6B in fiscal 2025 and $1.7B over the twelve months to September 30, 2026.

How much profit does Integra Lifesciences Holdings make?

Net income was -$516M in fiscal 2025 (net margin -31.6%).

Is Integra Lifesciences Holdings’s revenue growing?

Yes: revenue rose 1.5% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.